Sarepta Therapeutics falls on revenue miss, weak outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform
August 8, 2024 8:18 AM EDTEvercore ISI analyst Gavin Clark-Gartner upgraded Sarepta Therapeutics (NASDAQ: SRPT) from In Line to Outperform with a price target of $179.00 (from $185.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.
Shares of Sarepta Therapeutics closed at $140.06 yesterday.
... MoreSarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital
August 8, 2024 6:27 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $181.00 (from $182.00) while maintaining a Outperform rating.
The analyst comments "SRPT reported 2Q earnings, and we had the chance to follow up with mgmt afterwards. We came away... More
